先聲藥業(02096.HK)授出1184.1萬份受限制股份單位
格隆匯12月23日丨先聲藥業(02096.HK)公吿, 於2021年12月23日,根據2021年受限制股份單位計劃以零代價向合共147名獲選人士(為集團員工)授出合共1184.1萬份受限制股份單位,相當於1184.1萬股相關股份,惟尚待承授人接納。
授出合共1184.1萬份受限制股份單位將通過根據一般授權及按照2021年受限制股份單位計劃的條款向Tricor受託人發行及配發相關股份達成。於公吿日期,公司已根據一般授權發行及配發1964.9萬股股份。根據2021年受限制股份單位計劃,公司須以其內部資源支付相關股份的認購款,而Tricor受託人須以現金認購相關股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.